Treatment strategies are more important than drugs in the management of rheumatoid arthritis
- PMID: 32088801
- DOI: 10.1007/s10067-020-05001-x
Treatment strategies are more important than drugs in the management of rheumatoid arthritis
Abstract
The treatment of inflammatory arthritides has been changed dramatically in the past two decades with the introduction of the biological (b) disease-modifying anti-rheumatic drugs (DMARDs) as well as the targeting synthetic (ts) DMARDs that can be used as monotherapy or in combination with conventional synthetic (cs) DMARDs. The concept of treat to target (T2T) and tight control monitoring of disease activity represents a therapeutic paradigm of modern rheumatology. In rheumatoid arthritis (RA), this treatment approach has proven to be effective in many clinical trials and is now a well-established approach. The most common treatment strategies rely on the combination of csDMARDs (mainly methotrexate, sulfasalazine and hydroxychloroquine). This comes from different studies which compare the outcomes of combination therapies versus csDMARD monotherapy or versus methotrexate plus biologics in early RA patients. Here, we review the literature of the most important T2T studies for RA patients. The results showed that a tight control strategy appears to be more important than a specific drug to control RA. T2T approach aiming for remission or low disease activity can be achieved in early RA patients using less expensive drugs in comparison to newer drugs and this may need to be recognised in the future recommendations for the management of RA. KEY POINTS: • Tight-control and treat-to-target (T2T) strategies are the cornerstone in achieving remission or low disease activity in rheumatoid arthritis (RA) • A plethora of clinical trials has confirmed the efficacy of csDMARDs when the tight-control and T2T strategies are applied • T2T and tight-control strategies are a less expensive option in comparison to newer drugs and may be recognised in the future recommendations for the management of RA. • Treatment decisions and strategies are more important than just the drugs.
Keywords: RA; Tight control; Treat to target; bDMARDs; csDMARDs; tsDMARDs.
References
-
- Smolen JS, Landewe R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977. https://doi.org/10.1136/annrheumdis-2016-210715 - DOI - PubMed
-
- Drosos AA, Psychos D, Andonopoulos AP, Stefanaki-Nikou S, Tsianos EB, Moutsopoulos HM (1990) Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up. Clin Rheumatol 9:333–341. https://doi.org/10.1007/bf02114393 - DOI - PubMed
-
- Drosos AA, Karantanas AH, Psychos D, Tsampoulas C, Moutsopoulos HM (1990) Can treatment with methotrexate influence the radiological progression of rheumatoid arthritis? Clin Rheumatol 9:342–345. https://doi.org/10.1007/bf02114394 - DOI - PubMed
-
- Drosos AA, Pelechas E, Voulgari PV (2019) Rheumatoid arthritis treatment. A Back to the drawing board project or high expectations for low unmet needs? J Clin Med 8(8):E1237. https://doi.org/10.3390/jcm8081237 - DOI - PubMed
-
- Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA (2019) Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. Semin Arthritis Rheum 48:597–602. https://doi.org/10.1016/j.semarthrit.2018.06.003 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
